lulizumab pegol   Click here for help

GtoPdb Ligand ID: 8460

Synonyms: BMS-931699 | BMS931699
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lulizumab pegol is a humanised PEGylated anti-CD28 antibody-based biologic, developed as a potential treatment for autoimmune diseases. This so-called domain antibody (dAb) contains the smallest functional binding unit and lacks the divalent structure characteristic of a complete antibody [3]. PEGylation improves solubility and extends circulating half-life [2].
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
A Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE) is underway (June 2015).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
CD28 is reported to be involved in the activation T-cells [1,4], which are important drivers of autoimmunity. T cells with no CD28 exhibit impaired T-helper 2 (Th2) responses indicating that CD28 is required for the initiation of the T cell response to antigen [1]. Blockade of CD28 with lulizumab blocks T cell activation, and due to the antibody structure actually drives the T cells in to a state of immune tolerance (anergy) [3].